REV 5901 is a competitive and orally active antagonist of leukotriene receptor , with a K i of 0.7 μM. REV 5901 is also a 5-lipoxygenase inhibitor. REV 5901 can be used for the research of asthma in which leukotriene release be involved. REV 5901 can be used for the study of colon carcinoma.
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Signaling Pathways > Leukotriene Receptor | Products > Signaling Pathways > Lipoxygenase
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.